SAXENDA (liraglutide [rDNA origin] injection)
This slideshow reviews drug information for SAXENDA (liraglutide [rDNA origin] injection) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult overweight or obese patients.
Central obesity is associated with sleep disorders in overweightmiddle-aged men, researchers reported online in theJournal of Sleep Research.
A team led by Sulin Cheng, PhD, of the University ofJyväskylä, Jyväskylä, Finland, studied 211 Finnish men aged30–65 years. Among the 163 overweight or obese subjects,40 had insomnia only, 23 had obstructive sleep apnea only, 24 had both,and 76 had neither.
Among the overweight men, the groups with sleep disordershad higher fat mass in the trunk and android regions than the group without sleepdisorders. In addition, the insomnia-only group had a lower level of leisure-timephysical activity and higher intake of saturated fatty acids than the groups withoutsleep disorders.